Erratum: EMerging BiomARKers in inflammatory bowel disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for crohn's disease activity: Role of cross-sectional imaging (American Journal of Gastroenterology (2013) 108 (1891-1900) DOI: 10.1038/ajg.2013.354)